XML 32 R16.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Goodwill and Other Intangibles | 12 Months Ended
--- | ---
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangibles | Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2024 and 2023 were as follows:
|  | Automotive |  |  | Medical |  |  | Total |
Balance as of December 31, 2022 |  | $ | 73,069 |  |  | $ | 46,705 |  |  | $ | 119,774 |
Impairment of goodwill |  |  | — |  |  |  | (19,509 | ) |  |  | (19,509 | )
Currency translation and other |  |  | 3,627 |  |  |  | 181 |  |  |  | 3,808 |
Balance as of December 31, 2023 |  | $ | 76,696 |  |  | $ | 27,377 |  |  | $ | 104,073 |
Currency translation and other |  |  | (3,942 | ) |  |  | (528 | ) |  |  | (4,470 | )
Balance as of December 31, 2024 |  | $ | 72,754 |  |  | $ | 26,849 |  |  | $ | 99,603 |
Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2024 and 2023 were as follows:
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Accumulated Impairment |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 109,608 |  |  | $ | (67,787 | ) |  | $ | (5,477 | ) |  | $ | 36,344 |
Technology |  |  | 43,458 |  |  |  | (29,976 | ) |  |  | (24 | ) |  |  | 13,458 |
Product development costs |  |  | 18,019 |  |  |  | (17,849 | ) |  |  | — |  |  |  | 170 |
Software development |  |  | 1,007 |  |  |  | (201 | ) |  |  | — |  |  |  | 806 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 7,003 |  |  |  | — |  |  |  | (530 | ) |  |  | 6,473 |
Balance as of December 31, 2024 |  | $ | 179,095 |  |  | $ | (115,813 | ) |  | $ | (6,031 | ) |  | $ | 57,251 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Accumulated Impairment |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 115,465 |  |  | $ | (67,923 | ) |  | $ | (5,814 | ) |  | $ | 41,728 |
Technology |  |  | 45,861 |  |  |  | (29,292 | ) |  |  | (25 | ) |  |  | 16,544 |
Product development costs |  |  | 19,434 |  |  |  | (19,270 | ) |  |  | — |  |  |  | 164 |
Software development |  |  | 1,007 |  |  |  | — |  |  |  | — |  |  |  | 1,007 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 7,039 |  |  |  | — |  |  |  | — |  |  |  | 7,039 |
Balance as of December 31, 2023 |  | $ | 188,806 |  |  | $ | (116,485 | ) |  | $ | (5,839 | ) |  | $ | 66,482 |
During the first quarter of 2024, we recorded a non-cash impairment charge of $530 for one of our Medical tradenames. As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10%. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $19,509. The Company performed its annual assessment of the Medical reporting unit goodwill as of December 31, 2024 and 2023 utilizing quantitative approaches and determined the fair value of the Medical reporting unit exceeded its carrying value at each date. The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions. In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore would require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. We are not presently aware of any other events or circumstances that would require us to revise the carrying value of our goodwill or other intangible assets as of December 31, 2024. A total of $7,019, $8,290, and $9,018 in other intangible assets were amortized in 2024, 2023 and 2022, respectively. An estimate of future amortization of other intangible assets, is as follows:
2025 |  | $ | 6,860 |
2026 |  |  | 6,424 |
2027 |  |  | 6,337 |
2028 |  |  | 6,276 |
2029 |  |  | 5,598 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration